Posted in

New Blood Test Optimizes Fetal Growth Restriction Diagnosis

•Posted inObstetrics and Gynaecology

Distinguishing pathological Fetal Growth Restriction (FGR) from constitutionally small-for-gestational-age (SGA) fetuses presents a significant clinical hurdle. Obstetricians now leverage the maternal sFlt-1/PlGF ratio to assess placental angiogenic imbalance, a key indicator of placental insufficiency. Therefore, this critical biomarker helps accurately classify high-risk pregnancies, guiding surveillance and management decisions.

The sFlt-1/PlGF Ratio in Clinical Differentiation

Systematic reviews covering over 25,000 pregnancies confirm that FGR consistently shows a higher sFlt-1/PlGF ratio compared to both appropriate-for-gestational-age (AGA) and SGA pregnancies. SGA fetuses exhibit only a modest or nonexistent elevation. Furthermore, pooled data demonstrates a significantly higher log-transformed ratio in FGR than in SGA (SMD 0.58, 95% CI 0.35–0.81). This difference is most pronounced in cases of early-onset placental FGR. Because of this high performance, the ratio serves as an invaluable adjunctive tool to conventional Doppler and ultrasound.

Guiding Management with Angiogenic Biomarkers

Elevated sFlt-1/PlGF values strongly suggest placental pathology. They do not strictly discriminate between FGR and preeclampsia (PE), which often coexist. Specifically, the cut-off points used for PE prediction, such as 38, 85, and 110, predict adverse perinatal outcomes (APO) in early-onset FGR/SGA cases. Conversely, a normal sFlt-1/PlGF ratio supports expectant management for SGA when ultrasound and Doppler are reassuring. Rising values or those above established cut-offs warrant closer surveillance and prompt intervention. Furthermore, a rapid daily increase in the ratio correlates with a shorter time to delivery, reflecting disease progression. Physicians must also note that a very low ratio, though atypical, can indicate underlying genetic disorders, requiring analysis of both markers.

Frequently Asked Questions

Q1: What is the primary clinical challenge the sFlt-1/PlGF ratio addresses?

The primary clinical challenge is accurately distinguishing pathological Fetal Growth Restriction (FGR) from benign, constitutionally small-for-gestational-age (SGA) fetuses. The ratio helps identify true placental insufficiency.

Q2: How do sFlt-1/PlGF ratios differ between FGR and SGA pregnancies?

FGR pregnancies exhibit a consistently and significantly higher sFlt-1/PlGF ratio than SGA pregnancies. SGA fetuses typically show modest or no elevation, which supports the constitutional smallness diagnosis.

Q3: When do elevated sFlt-1/PlGF values warrant intervention?

Elevated values warrant closer surveillance and potential intervention because they indicate underlying placental insufficiency. Furthermore, a normal ratio, when combined with reassuring ultrasound and Doppler results, supports expectant management in SGA cases.

References

  1. Byrne Z et al. Maternal sFlt-1/PlGF Ratio to Distinguish Pathological Fetal Growth Restriction From Constitutional Smallness: Systematic Review. BJOG. 2026 Jan 05. doi: 10.1111/1471-0528.70128. PMID: 41489038.
  2. Savvidou MG et al. sFlt-1 to PlGF ratio cut-offs to predict adverse pregnancy outcomes in early-onset FGR and SGA: a prospective observational study. J Obstet Gynaecol. 2022 Oct;42(7):2840-2845.
  3. Pappalardo S et al. Very low sFlt-1/PlGF ratio in foetal growth restriction: clinical insights from a case study. J Obstet Gynaecol Res. 2024 Oct;50(10):2618-2621.
  4. Hasanoglu A et al. Course of the sFlt-1/PlGF ratio in fetal growth restriction and correlation with biometric measurements, feto-maternal Doppler parameters and time to delivery. J Matern Fetal Neonatal Med. 22 Mar 2024.